Dulaglutide
Weekly-administered long-acting GLP-1 receptor agonist API for chronic diabetes management. Glucose-dependent insulin promotion with glucagon inhibition, gastric emptying delay, and body weight reduction.
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist consisting of a GLP-1 analog covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment. It is approved for the treatment of type 2 diabetes mellitus (T2DM) as a once-weekly subcutaneous injection, offering sustained glycemic control with reduced dosing frequency compared to daily GLP-1 agonists.
| CAS | 923950-08-7 |
| Molecular Formula | C₁₄₉H₂₂₁N₃₇O₄₉ |
| Molecular Weight | 3314.62 g/mol |
| Category | GLP-1 & Incretin Metabolic Peptides |
| Purity | >=99% (HPLC) |
| Status | GMP-compliant, FDA-ready |
| Applications | Type 2 diabetes, cardiovascular risk reduction, weight management, chronic glycemic control |
| CAS | 923950-08-7 |
|---|---|
| Applications | cardiovascular risk reduction, chronic glycemic control, Type 2 diabetes, weight management |
Related products
-
Tirzepatide
CAS: 2023788-19-2Applications: Advanced obesity, metabolic syndrome, Type 2 diabetes -
GLP-1 (7-37)
CAS: 106612-94-6Applications: Diabetes Research, GLP-1 Analog Development, metabolic syndrome -
Setmelanotide
CAS: 920014-72-8Applications: Appetite Regulation, Genetic Obesity, MC4R Agonist, metabolic syndrome -
Leuprorelin Acetate
CAS: 74381-53-6Applications: Breast Cancer, Endometriosis, Precocious Puberty, Prostate Cancer